China Traditional Chinese Medicine announced interim results for the six months ended June 30, 2026, with a turnover of 5.438 billion yuan, a year-on-year decrease of 27.1%; shareholders' losses of 776 million yuan, an increase of 619.3% over the previous year; and a basic loss of 15.42 points per share. According to the announcement, during the reporting period, the Group's revenue decreased by 27.1% year-on-year. Mainly, the Chinese medicine formula granule business was affected by industry policy adjustments and changes in the market environment. Demand for terminals declined, and sales volume declined in the current period.

China Traditional Chinese Medicine announced interim results for the six months ended June 30, 2026, with a turnover of 5.438 billion yuan, a year-on-year decrease of 27.1%; shareholders' losses of 776 million yuan, an increase of 619.3% over the previous year; and a basic loss of 15.42 points per share. According to the announcement, during the reporting period, the Group's revenue decreased by 27.1% year-on-year. Mainly, the Chinese medicine formula granule business was affected by industry policy adjustments and changes in the market environment. Demand for terminals declined, and sales volume declined in the current period.